Immunotherapy: Open Access

Immunotherapy: Open Access
Open Access

ISSN: 2471-9552

+44 1223 790975

Peng Wu

College of Life Sciences, Shihezi University, Xinjiang, China

  • Research Article   
    A Novel PD-L1 Nanobody Validates that Immune Cell Suppressed by Pd-L1 May Always Exist in the Body
    Author(s): Chuangfu Chen*, Peng Wu and Jiao Jiao

    Background: PD-L1 is expressed widely in the body. PD-1-PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. Researchers have shown that blocking PD-L1 in both the early and chronic stages of the disease may increase T cell activity. What’s more, we tried to find the improvement of PD-L1 on the body's immunity. Methods: Nanobody binding to PD-L1 was prepared, and the PD-L1 nanobody was verified by SDS-PAGE and Western-Blot. Affinity detection of PD-L1 Nanobody and PD-L1 receptor was made by ELISA and flow cytometry. The cytotoxicity of the PD-L1 nanobody was tested by BHK-21, MDBK, and sheep kidney cells. The inhibitory effect on tumor model was verified. PD-L1 nanobody activated the macrophages was tested. Staphylococcus aureus was used to test the prot.. View More»

    Abstract HTML PDF